Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women

National Health and Nutrition Examination Survey 19992004

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Aim. Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills OCP treatment duration to compare never-treated women with four OCP-treatment groups <1, 15, 510 and >10 years. Methods. The NHANES 19992004 database was used to evaluate 2089 healthy, pre-menopausal women, aged 1855 years, with or without OCP history, no other hormonal treatment or history of systemic conditions. Outcome measures included body mass, central obesity, blood pressure, glycemia, insulinemia, lipid profile and inflammation. Analyses evaluated differences in prevalence of Metabolic Syndrome MetS, constituent MetS and other clinical risk criteria, as well as outcome magnitudes. Analyses controlled for demographic and health-related variables, and study-eligible conditions. Results. Relative to other groups, women with >10 years OCP-use, and to some extent those with 510 years treatment, displayed no differences in prevalence of MetS and most risk criteria. Further analysis showed that, relative to women treated for <5 years, those with more prolonged OCP treatment displayed lower body mass and fasting glycemia with higher HDL-c levels, but more elevated LDL-c and total cholesterol. Conclusions. The findings of both beneficial and detrimental subclinical cardiometabolic differences with more long-term OCP-treatment reinforces the need to monitor changes in these factors within the context of the treated patient's risk-benefit profile. However, because the magnitude of these differences was small, relative to normative ranges, it may be concluded that OCPs, as used in recent decades, are unlikely to markedly affect cardiometabolic risk.

Original languageEnglish
Pages (from-to)441-449
Number of pages9
JournalGynecological Endocrinology
Volume25
Issue number7
DOIs
StatePublished - Nov 9 2009

Fingerprint

Metabolic Syndrome X
Nutrition Surveys
Women's Health
Oral Contraceptives
Therapeutics
Abdominal Obesity
Fasting
History
Cholesterol
Demography
Outcome Assessment (Health Care)
Databases
Blood Pressure
Inflammation
Lipids
Health

Keywords

  • Cardiovascular
  • Metabolic syndrome
  • Oral contraceptives
  • Pre-menopausal

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Obstetrics and Gynecology

Cite this

@article{05ff46f2195a483986dcbc8a3f517e2a,
title = "Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women: National Health and Nutrition Examination Survey 19992004",
abstract = "Aim. Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills OCP treatment duration to compare never-treated women with four OCP-treatment groups <1, 15, 510 and >10 years. Methods. The NHANES 19992004 database was used to evaluate 2089 healthy, pre-menopausal women, aged 1855 years, with or without OCP history, no other hormonal treatment or history of systemic conditions. Outcome measures included body mass, central obesity, blood pressure, glycemia, insulinemia, lipid profile and inflammation. Analyses evaluated differences in prevalence of Metabolic Syndrome MetS, constituent MetS and other clinical risk criteria, as well as outcome magnitudes. Analyses controlled for demographic and health-related variables, and study-eligible conditions. Results. Relative to other groups, women with >10 years OCP-use, and to some extent those with 510 years treatment, displayed no differences in prevalence of MetS and most risk criteria. Further analysis showed that, relative to women treated for <5 years, those with more prolonged OCP treatment displayed lower body mass and fasting glycemia with higher HDL-c levels, but more elevated LDL-c and total cholesterol. Conclusions. The findings of both beneficial and detrimental subclinical cardiometabolic differences with more long-term OCP-treatment reinforces the need to monitor changes in these factors within the context of the treated patient's risk-benefit profile. However, because the magnitude of these differences was small, relative to normative ranges, it may be concluded that OCPs, as used in recent decades, are unlikely to markedly affect cardiometabolic risk.",
keywords = "Cardiovascular, Metabolic syndrome, Oral contraceptives, Pre-menopausal",
author = "Barry Hurwitz and Nicole Henry and Goldberg, {Ronald B}",
year = "2009",
month = "11",
day = "9",
doi = "10.1080/09513590902770149",
language = "English",
volume = "25",
pages = "441--449",
journal = "Gynecological Endocrinology",
issn = "0951-3590",
publisher = "Informa Healthcare",
number = "7",

}

TY - JOUR

T1 - Long-term oral contraceptive treatment, metabolic syndrome and measures of cardiovascular risk in pre-menopausal women

T2 - National Health and Nutrition Examination Survey 19992004

AU - Hurwitz, Barry

AU - Henry, Nicole

AU - Goldberg, Ronald B

PY - 2009/11/9

Y1 - 2009/11/9

N2 - Aim. Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills OCP treatment duration to compare never-treated women with four OCP-treatment groups <1, 15, 510 and >10 years. Methods. The NHANES 19992004 database was used to evaluate 2089 healthy, pre-menopausal women, aged 1855 years, with or without OCP history, no other hormonal treatment or history of systemic conditions. Outcome measures included body mass, central obesity, blood pressure, glycemia, insulinemia, lipid profile and inflammation. Analyses evaluated differences in prevalence of Metabolic Syndrome MetS, constituent MetS and other clinical risk criteria, as well as outcome magnitudes. Analyses controlled for demographic and health-related variables, and study-eligible conditions. Results. Relative to other groups, women with >10 years OCP-use, and to some extent those with 510 years treatment, displayed no differences in prevalence of MetS and most risk criteria. Further analysis showed that, relative to women treated for <5 years, those with more prolonged OCP treatment displayed lower body mass and fasting glycemia with higher HDL-c levels, but more elevated LDL-c and total cholesterol. Conclusions. The findings of both beneficial and detrimental subclinical cardiometabolic differences with more long-term OCP-treatment reinforces the need to monitor changes in these factors within the context of the treated patient's risk-benefit profile. However, because the magnitude of these differences was small, relative to normative ranges, it may be concluded that OCPs, as used in recent decades, are unlikely to markedly affect cardiometabolic risk.

AB - Aim. Differences in subclinical cardiometabolic measures were examined as a function of oral contraceptive pills OCP treatment duration to compare never-treated women with four OCP-treatment groups <1, 15, 510 and >10 years. Methods. The NHANES 19992004 database was used to evaluate 2089 healthy, pre-menopausal women, aged 1855 years, with or without OCP history, no other hormonal treatment or history of systemic conditions. Outcome measures included body mass, central obesity, blood pressure, glycemia, insulinemia, lipid profile and inflammation. Analyses evaluated differences in prevalence of Metabolic Syndrome MetS, constituent MetS and other clinical risk criteria, as well as outcome magnitudes. Analyses controlled for demographic and health-related variables, and study-eligible conditions. Results. Relative to other groups, women with >10 years OCP-use, and to some extent those with 510 years treatment, displayed no differences in prevalence of MetS and most risk criteria. Further analysis showed that, relative to women treated for <5 years, those with more prolonged OCP treatment displayed lower body mass and fasting glycemia with higher HDL-c levels, but more elevated LDL-c and total cholesterol. Conclusions. The findings of both beneficial and detrimental subclinical cardiometabolic differences with more long-term OCP-treatment reinforces the need to monitor changes in these factors within the context of the treated patient's risk-benefit profile. However, because the magnitude of these differences was small, relative to normative ranges, it may be concluded that OCPs, as used in recent decades, are unlikely to markedly affect cardiometabolic risk.

KW - Cardiovascular

KW - Metabolic syndrome

KW - Oral contraceptives

KW - Pre-menopausal

UR - http://www.scopus.com/inward/record.url?scp=70350686383&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350686383&partnerID=8YFLogxK

U2 - 10.1080/09513590902770149

DO - 10.1080/09513590902770149

M3 - Article

VL - 25

SP - 441

EP - 449

JO - Gynecological Endocrinology

JF - Gynecological Endocrinology

SN - 0951-3590

IS - 7

ER -